Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe why lung disease raises COVID-19 risk

NCT ID NCT04444609

Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study investigates how the immune system responds to COVID-19 in people with chronic lung conditions like asthma, COPD, or cystic fibrosis, compared to those without lung disease. Researchers collect blood, sputum, and nasal samples to measure immune signals and gene activity. The goal is to uncover why some patients develop severe illness, which could guide future treatments or vaccines.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal why people with lung disease are more vulnerable to severe COVID-19, pointing toward better prevention or treatment strategies.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and findings may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

161 people

The number who actually took part.

Started

Jun 2020

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with swab confirmed COVID-19 and underlying chronic lung disease (n=60) * Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia) * Mild/Moderate ( n =30) Absence of features of severe disease Subjects with swab confirmed COVID-19 and no chronic lung disease (n=60) * Severe (n=30) (defined by presence of ARDS, sepsis or severe pneumonia) * Mild/Moderate ( n =30) Absence of features of severe disease Subjects with chronic lung disease (identified as requiring shielding based on severity) but no COVID-19 (n=80) * Asthma (defined as severe) - (n=20) * CF (FEV1% predicted baseline \<50%) - (n=20) * COPD (FEV1% predicted baseline \<50%) - (n=20) * Idiopathic Pulmonary Fibrosis (n=20) 3.Healthy subjects with no COVID-19 (n=30)

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. All patients ≥16 years old with confirmation of COVID-19 2. All patients ≥ 16 years old with chronic lung disease (CF, non-CF bronchiectasis, asthma, COPD or Idiopathic Pulmonary Fibrosis) or with no evidence of prior chronic lung disease 3. Healthy volunteers Exclusion Criteria: None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, human are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome chronic obstructive pulmonary disease COVID-19 immune system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS, human COVID -19 Immune system disorder SARS-CoV-2

Contacts and locations

Locations

  • Royal Brompton & Harefileld NHS Trusts

    London, London, SW3 6PP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.